Actieve functies van Noriyuki Komuro
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AGC Biologics A/S
AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Voorzitter | - | - |
Loopbaan van Noriyuki Komuro
Eerdere bekende functies van Noriyuki Komuro
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MOLMED S.P.A. | Voorzitter | 31-07-2020 | - |
Statistieken
Internationaal
Denemarken | 2 |
Italië | 2 |
Operationeel
Chairman | 2 |
Sectoraal
Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
AGC Biologics A/S
AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Health Technology |
AGC Biologics SpA
AGC Biologics SpA Pharmaceuticals: MajorHealth Technology AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy. | Health Technology |
- Beurs
- Insiders
- Noriyuki Komuro
- Ervaring